- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02470247
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients (IPC-Angio)
IPC-Angio Trial : Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy (Post-diagnostic Imaging) in Patients at High Risk of Contrast-induced Nephropathy
Diagnostic imaging for vascular investigations and endovascular procedures frequently require the use of contrast medium. Besides contrast medium-induced hypersensitivity, an acute kidney injury can appear: the contrast-induced nephropathy (NPCI).
NPCI is associated with an increase of patients' morbidity and mortality. One of the conventional methods proposed to limit this NPCI is an oral administration of N-acetylcysteine (NAC) associated with hydration performed 12 hours before and 12 hours after the injection. However, in some patients this method cannot be performed due to a high risk of heart failure although they are generally at high risk of NPCI.
Recently, it has been shown, in a randomized trial, that remote ischemic preconditioning (several cycles of upper-arm ischemia-reperfusion with a pressure cuff inflator) associated with hydratation and NAC reduced the occurrence of NPCI after a coronary angiography as compared with NAC and hydration only. .
We hypothesized that the use of RIPC in patients at high risk of NPCI and who cannot receive NAC and hydratation (e.g. patients with aortic stenosis and eligible for Transcatheter Aortic Valve Implantation (TAVI)) could be promising.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design :
Prospective, single-center, randomized, controlled, single-blind, with RIPC procedure (Pre-CI) versus "SHAM" ischemic preconditioning (SHAM Pre -CI) (control). This test will follow the CONSORT Statement (http://www.consort-statement.org/).
This is a randomized, controlled, single-blind trial, assessing the incidence of NPCI (after a CTA ) between two group of patients, one receiving RIPC procedure and the other group receiving a "SHAM" RIPC (control group).
RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.
RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes. The "SHAM" RIPC will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
Main objective :
To assess the efficacy of remote ischemic preconditioning (RIPC) in preventing contrast-induced nephropathy (NPCI) after injected CT scanner in patients at high risk of NPCI.
Secondary objectives :
- To assess the effects of RIPC on a second marker of renal failure (Cystatin C ) ;
- To determine the pathophysiological mechanisms involved in the RIPC (role of oxidative stress ; for the first 40 patients) ;
- To assess the effect of RIPC on renal function after a second injection of contrast-medium during coronary angiography performed 2 to 4 days after the injected CTA ;
- To assess the tolerance of RIPC procedure ;
- To assess the impact on mortality at 6 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Britanny
-
Rennes, Britanny, France, 35033
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age greater than 18 years, no upper age limit ;
- Patient which may hospitalized for a medical check-up before a percutaneous aortic valve implantation (CTA and coronarography);
- Patient at risk for NPCI defined by a Mehran risk classification system ≥11 (Annexe 2) ;
- Willing to provide free and informed written consent
Exclusion Criteria:
- Pathology of the upper-limbs limiting the use of the cuff (bilateral amputation, arteriovenous fistula);
- Critical renal disease requiring hemodialysis ;
- Person who is not affiliated to a health care system insurance
- Inability to understand the instructions of the study;
- Absolute contraindication to of iodinated contrast medium injection (anaphylactic shock history to contrast media, especially Xenetix, clearance (MDRD) less than 30mL/min/1.73m2) ;
- Pregnancy
- Simultaneous participation in other protocol;
- Person with legal protection, person deprived of liberty.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Remote ischemic preconditioning
Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion. RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes. |
RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion. RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes. |
|
Sham Comparator: SHAM remote ischemic preconditioning
The SHAM Remote Ischemic Preconditioning ("SHAM" RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
|
The SHAM Remote Ischemic Preconditioning ("SHAM" RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of NPCI
Time Frame: 48 hours
|
Incidence of NPCI defined as an increase in serum creatinine ≥ 0.5 mg / dL or a relative increase of 25 % above baseline at 48 hours after contrast medium exposure.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cystatin C
Time Frame: 2 days
|
Changes of serum Cystatin C between day 0 and day 1, and day 0 and day 2.
|
2 days
|
|
Oxydative stress
Time Frame: 24 hours
|
Changes in markers of oxydative stress (in the first 40 patients included) :
|
24 hours
|
|
Renal function
Time Frame: 6 days
|
Changes in serum creatinine and Cystatin C between day 0 and measured values after coronarography (day 6 ).
|
6 days
|
|
Pain
Time Frame: Day 0
|
A standardized pain scale (ranged from 0 to 10; 0 : no pain; 10 : maximum of pain).
|
Day 0
|
|
Mortality
Time Frame: 6 months
|
Assessment of mortality at six months.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guillaume MAHE, MD, Rennes University Hospital
Publications and helpful links
General Publications
- Belabbas D, Koch C, Chaudru S, Lederlin M, Laviolle B, Le Pabic E, Boulmier D, Heautot JF, Mahe G. Effects of Remote Ischemic Pre-Conditioning to Prevent Contrast-Induced Nephropathy after Intravenous Contrast Medium Injection: A Randomized Controlled Trial. Korean J Radiol. 2020 Nov;21(11):1230-1238. doi: 10.3348/kjr.2019.0916. Epub 2020 Jul 27.
- Koch C, Chaudru S, Lederlin M, Jaquinandi V, Kaladji A, Mahe G. Remote Ischemic Preconditioning and Contrast-Induced Nephropathy: A Systematic Review. Ann Vasc Surg. 2016 Apr;32:176-87. doi: 10.1016/j.avsg.2015.10.017. Epub 2016 Jan 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC14_9899_IPC-Angio Trial
- 150058B-11 (Other Identifier: ANSM)
- 15/07-969 (Other Identifier: Comité de Protection des Personnes)
- 2015-A00076-43 (Other Identifier: ANSM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephropathy
-
Josep M CruzadoWyeth is now a wholly owned subsidiary of PfizerCompletedGlomerulonephritis, IGA | IGA Nephropathy | Nephropathy, IGASpain
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Russian Academy of Medical SciencesRussian Scientific Center of SurgeryCompletedAcute Graft Rejection | Chronic Allograft Nephropathy | Polyomavirus-related Transplant NephropathyRussian Federation
-
Minia UniversityNot yet recruitingContrast-induced Nephropathy
-
Alexion Pharmaceuticals, Inc.AstraZenecaRecruitingPrimary Membranous NephropathySpain, China, United States, Taiwan, United Kingdom, France, Brazil, Argentina, Australia, Italy
-
Assiut UniversityUnknownObstructive Nephropathy
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... and other collaboratorsCompletedMEMBRANOUS NEPHROPATHYSpain
-
Rigel PharmaceuticalsWithdrawn
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruiting
-
Excyte Biopharma LtdNot yet recruitingPrimary Membranous Nephropathy
Clinical Trials on Remote Ischemic Preconditioning (RIPC)
-
Medical University of LodzCompletedRemote Ischemic Preconditioning | Contrast Induced - Acute Kidney InjuryPoland
-
Institut für Pharmakologie und Präventive MedizinWithdrawnEffectivity of RIPC in Outcomes of TAVI ProcedureGermany
-
Xijing HospitalUnknownCardiac Surgery PatientsChina
-
Beijing Tiantan HospitalPeking University International HospitalSuspendedMoyamoya Disease | Remote Ischemic PreconditioningChina
-
VA Office of Research and DevelopmentRecruitingHeart Failure | Acute Kidney Injury | Percutaneous Coronary Intervention | Contrast Induced Nephropathy | Coronary AngiographyUnited States
-
Universität MünsterRecruitingSepsis | Acute Kidney Injury | Critically IllGermany
-
Fujian Medical UniversityThe First Affiliated Hospital of Dalian Medical University; Xiamen Cardiovascular...RecruitingAortic Dissection Type AChina
-
University Hospital MuensterElse Kröner Fresenius FoundationUnknownCardiac Surgery, Aortocoronary BypassGermany
-
Beijing Anzhen HospitalUnknown